Key result
Transcatheter therapies for severe tricuspid regurgitation are emerging as promising, less invasive alternatives to surgery, with several devices showing feasibility and safety in early studies.
Why the study?
Tricuspid regurgitation was historically underappreciated despite severe TR predicting higher mortality, prompting the need to better understand the tricuspid valve and evolving transcatheter treatment strategies.
Answers are grounded in this paper and cite their sources.
A review highlighting the prognostic impact of severe tricuspid regurgitation and the emerging transcatheter therapies for its treatment.
The tricuspid valve (TV) has been known as the forgotten valve. However, considering recent information from scientific studies, this nomenclature may need to be adjusted for the valve, which also needs to be better studied and understood. For decades, tricuspid regurgitation (TR) was not fully appreciated and was never the priority. However, studies have revealed that such pathology is related to a possible negative impact on prognosis of patients. Severe TR is a predictor of higher mortality. For the treatment of TR, repair or valve replacement can be performed. Repair techniques can be performed on the annulus (suture annuloplasty or ring implant), on the leaflets (e.g. triangular resection), on the cords (transfers or new cords) and on the papillary muscles (e.g. sliding technique). The anatomical characteristics of the TV determine the repair technique to be used. In some cases, valve repair is not possible and/or not indicated and valve replacement is selected based on the strategy. Nowadays transcatheter therapies have been used and studied. The main transcatheter strategies for the treatment of TR are based on reduction of the annulus (Cardioband, Trialign, TriCinch, Millipede and TRAIPTA), improvement of the leaflet coaptation (Mitraclip, FORMA device, PASCAL system, and TV occluder), reduction of the reflux for the vena cava system (Tric valve and Sapien valve implant), and valve implants (Navigate, Trisol, Sapien, Melody). In this context, there are still other devices (such as Tricentro, Pasta, etc.) being developed and tested throughout several phases of research. In the future, improved knowledge of the TV and the evolution of transcatheter treatments will alter the history of the TV. The transcatheter revolution is coming!
No takes yet. Share an insight, caveat, or question.
Oliveira et al. (2019) conducted a review in Tricuspid regurgitation. Transcatheter tricuspid valve therapies was evaluated. Transcatheter therapies for severe tricuspid regurgitation are emerging as promising, less invasive alternatives to surgery, with several devices showing feasibility and safety in early studies.
Synapse has enriched 10 related papers. Consider them for comparative context: